PD-L1 testing in advanced gastric cancer—what physicians who treat this disease must know—a literature review
Journal of Gastrointestinal Oncology · 2023-06 · 14 (3) · 1560-1575
DOI: 10.21037/jgo-22-1133 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastrointestinal Oncology, 2023-06. Verfasst von Renata D'Alpino Peixoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Oncoclinicas, São Paulo, Brazil. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and Objective: Immune checkpoint inhibition has shed light on a new era in cancer therapy, and randomized clinical trials have demonstrated that a meaningful portion of the overall population of metastatic gastric cancer (GC) patients may derive clinical benefit from immunotherapy, which raises the relevance in identifying predictive biomarkers. Programmed cell death-ligand 1 (PD-L1) expression has demonstrated a significant association between level of expression and the magnitude of benefit derived from immune checkpoint inhibition in GC. Nevertheless, this biomarker shows several pitfalls that must be considered in the therapeutic decision to incorporate immune checkpoint inhibition as the standard of care of GC, such as spatial and temporal heterogeneity, interobserver variability, immunohistochemistry (IHC) assay, and influence by chemotherapy or radiation therapy.
Methods
In the present comprehensive review, we revised the main studies regarding PD-L1 evaluation in GC. Key Content and Findings: Here we describe the molecular characteristics of the tumor microenvironment in GC, the obstacles in the interpretation of PD-L1 expression and present the data of the clinical trials that have evaluated the efficacy and safety of immune checkpoint inhibition and the association with the biomarker expression, both in first-line and later lines of therapy.
Conclusions
From the emerging predictive biomarkers for immune checkpoint inhibition, PD-L1 has demonstrated a meaningful association between level of expression in tumor microenvironment and the magnitude of benefit derived from immune checkpoint inhibition in GC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, Oncoclinicas, São Paulo, Brazil.
- Department of Gastrointestinal Medical Oncology, Oncoclinicas, Belo Horizonte, Brazil.
- Department of Gastrointestinal Medical Oncology, Oncoclinicas, Rio de Janeiro, Brazil.
- Department of Gastrointestinal Medical Oncology, Oncoclinicas, Salvador, Brazil.
Zitieren
APA
Peixoto, R. D., Mathias-Machado, M. C., Jácome, A., Gil, M., Fogacci, J., Sodré, B., Passarini, T., Chaves, A., Diniz, P. H., Lino, F., Palladino, A., Souto, M., de Castro, A. C., & Garicochea, B. (2023). PD-L1 testing in advanced gastric cancer—what physicians who treat this disease must know—a literature review. Journal of Gastrointestinal Oncology, 14(3), 1560-1575. https://doi.org/10.21037/jgo-22-1133
Vancouver
Peixoto RD, Mathias-Machado MC, Jácome A, Gil M, Fogacci J, Sodré B, et al. PD-L1 testing in advanced gastric cancer—what physicians who treat this disease must know—a literature review. Journal of Gastrointestinal Oncology. 2023;14(3):1560-1575. doi:10.21037/jgo-22-1133
BibTeX
@article{Peixoto2023,
author = {Peixoto, Renata D'Alpino and Mathias-Machado, Maria Cecilia and Jácome, Alexandre and Gil, Mariana and Fogacci, João and Sodré, Bárbara and Passarini, Thaís and Chaves, Aline and Diniz, Paulo Henrique and Lino, Flora and Palladino, Alexandre and Souto, Mirela and de Castro, Ana Carolina and Garicochea, Bernardo},
title = {PD-L1 testing in advanced gastric cancer—what physicians who treat this disease must know—a literature review},
journal = {Journal of Gastrointestinal Oncology},
year = {2023},
volume = {14},
number = {3},
pages = {1560--1575},
doi = {10.21037/jgo-22-1133}
}
EUVIMED